Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. May 25, 2021; 10(3): 86-96
Published online May 25, 2021. doi: 10.5501/wjv.v10.i3.86
Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients
Wattana Leowattana
Wattana Leowattana, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
Author contributions: Leowattana W collected the data and wrote the paper.
Conflict-of-interest statement: The author declares no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Wattana Leowattana, BSc, MD, MSc, PhD, Associate Professor, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Rachatawee, Bangkok 10400, Thailand.
Received: January 28, 2021
Peer-review started: January 28, 2021
First decision: February 24, 2021
Revised: March 10, 2021
Accepted: April 26, 2021
Article in press: April 26, 2021
Published online: May 25, 2021
Core Tip

Core Tip: With more than 100 million confirmed cases worldwide, hepatobiliary injury has been reported in many coronavirus disease 2019 (COVID-19) patients. The association between COVID-19 and hepatobiliary injury refers to any hepatobiliary damage during disease progression and treatment in COVID-19 patients with or without chronic liver diseases or common medications. Angiotensin-converting enzyme 2 receptor may be a significant factor in hepatobiliary derangement due to its high expression in cholangiocytes, and it is also an entry point of severe acute respiratory syndrome coronaviruses 2. Moreover, drug-induced liver injury and cytokine storm may be an added risk in severe clinical outcomes. Close monitoring of liver function in COVID-19 patients is mandatory.